Aptus is a drug discovery company that uses its proprietary technologies to develop therapeutics targeting G-Protein Coupled Receptors (GPCRs). Its leading technology is AptuScreen, a highly sensitive, cost-effective, homogeneous assay that directly measures cyclic AMP (cAMP) formation resulting from ligand-receptor binding. Aptus is using AptuScreen in its own drug discovery efforts as well as licensing rights to use of the technology to pharmaceutical and biotechnology companies